Mitsubishi UFJ Trust & Banking Corp increased its stake in Amgen, Inc. (NASDAQ:AMGN) by 4.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 542,101 shares of the medical research company’s stock after purchasing an additional 25,388 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp owned about 0.09% of Amgen worth $99,757,000 at the end of the most recent quarter.
A number of other hedge funds also recently bought and sold shares of AMGN. Norges Bank acquired a new stake in Amgen in the 4th quarter valued at about $1,283,248,000. Thoroughbred Financial Services LLC lifted its holdings in Amgen by 19,447.3% in the 2nd quarter. Thoroughbred Financial Services LLC now owns 1,805,392 shares of the medical research company’s stock valued at $180,539,000 after acquiring an additional 1,796,156 shares during the last quarter. Ruffer LLP acquired a new stake in Amgen in the 2nd quarter valued at about $192,788,000. Ellis Investment Partners LLC lifted its holdings in Amgen by 18,906.7% in the 1st quarter. Ellis Investment Partners LLC now owns 605,934 shares of the medical research company’s stock valued at $605,000 after acquiring an additional 602,746 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Amgen by 5.8% in the 4th quarter. Geode Capital Management LLC now owns 8,850,224 shares of the medical research company’s stock valued at $1,720,250,000 after acquiring an additional 482,760 shares during the last quarter. 78.01% of the stock is owned by institutional investors and hedge funds.
AMGN has been the topic of several recent analyst reports. BMO Capital Markets set a $230.00 price objective on Amgen and gave the stock a “buy” rating in a report on Wednesday, July 31st. Evercore ISI restated a “hold” rating on shares of Amgen in a report on Sunday, August 11th. Wells Fargo & Co boosted their price objective on Amgen from $197.00 to $202.00 and gave the stock a “market perform” rating in a report on Monday, August 12th. JPMorgan Chase & Co. restated a “hold” rating on shares of Amgen in a report on Friday, August 9th. Finally, Oppenheimer boosted their price objective on Amgen from $210.00 to $230.00 and gave the stock an “outperform” rating in a report on Tuesday, August 13th. Ten investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $212.94.
In other news, Director R Sanders Williams sold 425 shares of the company’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $183.04, for a total value of $77,792.00. Following the transaction, the director now owns 16,336 shares in the company, valued at approximately $2,990,141.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ronald D. Sugar sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 5th. The shares were sold at an average price of $175.68, for a total value of $351,360.00. Following the completion of the sale, the director now directly owns 16,219 shares of the company’s stock, valued at approximately $2,849,353.92. The disclosure for this sale can be found here. Insiders sold a total of 4,425 shares of company stock worth $804,312 in the last quarter. 0.25% of the stock is owned by corporate insiders.
Shares of AMGN traded down $4.34 during trading hours on Friday, reaching $199.08. The company’s stock had a trading volume of 2,734,319 shares, compared to its average volume of 3,954,342. The firm has a market cap of $121.99 billion, a price-to-earnings ratio of 13.83, a P/E/G ratio of 2.45 and a beta of 1.19. Amgen, Inc. has a 1-year low of $166.30 and a 1-year high of $211.90. The company has a quick ratio of 2.60, a current ratio of 2.89 and a debt-to-equity ratio of 2.58. The company has a 50 day moving average of $186.41 and a two-hundred day moving average of $183.47.
Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, July 30th. The medical research company reported $3.97 earnings per share for the quarter, beating analysts’ consensus estimates of $3.58 by $0.39. The company had revenue of $5.87 billion for the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a return on equity of 76.17% and a net margin of 33.78%. The firm’s quarterly revenue was down 3.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.83 EPS. As a group, analysts forecast that Amgen, Inc. will post 14.26 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 6th. Stockholders of record on Thursday, August 15th will be issued a $1.45 dividend. The ex-dividend date of this dividend is Wednesday, August 14th. This represents a $5.80 dividend on an annualized basis and a dividend yield of 2.91%. Amgen’s dividend payout ratio is 40.28%.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Featured Article: What is Call Option Volume?
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.